Leerink Partners Initiates Medincell Coverage with Outperform Rating Following UZEDY Risperidone LAI FDA Approvals

Key Takeaways

• Leerink Partners initiated coverage of Medincell with an Outperform recommendation following successful FDA approvals
• UZEDY (risperidone LAI) received FDA approval for schizophrenia in April 2023 and Bipolar I Disorder in October 2025
• Medincell’s BEPO technology platform shows promise with olanzapine LAI NDA submitted to FDA for schizophrenia treatment

---

Leerink Partners Backs Medincell’s Growth Potential

Leerink Partners has initiated coverage of French pharmaceutical company Medincell with an Outperform recommendation, highlighting the success of the company’s long-acting injectable (LAI) psychiatric medications powered by its proprietary BEPO technology.

UZEDY Marks Major Regulatory Milestone

Medincell’s risperidone LAI, marketed as UZEDY by Teva Pharmaceuticals in the United States, represents the first FDA-approved treatment utilizing the company’s innovative BEPO technology platform. The drug initially received approval for schizophrenia treatment in April 2023, followed by an expanded indication for Bipolar I Disorder in October 2025.

The BEPO (BioErodible Polymer) technology offers a significant advancement in psychiatric care by providing extended-release formulations that improve patient compliance and reduce dosing frequency compared to traditional oral medications.

International Expansion Gains Momentum

Beyond the U.S. market, Medincell has secured regulatory approvals for risperidone LAI in key international markets. Health authorities in both Canada and South Korea approved the treatment for schizophrenia in 2025, expanding the global reach of the BEPO-based therapy.

Pipeline Progress with Olanzapine LAI

Building on the success of risperidone LAI, Medincell has submitted a New Drug Application (NDA) to the U.S. FDA for olanzapine LAI as a once-monthly treatment for schizophrenia in adults. This submission demonstrates the versatility of the BEPO platform and the company’s commitment to expanding treatment options for patients with serious mental health conditions.

Market Implications

The Outperform rating from Leerink Partners reflects growing confidence in Medincell’s ability to capitalize on the significant market opportunity for long-acting injectable psychiatric medications. The global antipsychotic drugs market continues to expand as healthcare providers seek solutions that improve medication adherence and patient outcomes.

---

Frequently Asked Questions

What makes UZEDY different from other schizophrenia treatments?

UZEDY uses Medincell’s proprietary BEPO technology to provide long-acting injection therapy, improving patient compliance compared to daily oral medications and offering extended symptom control.

When will olanzapine LAI be available if approved?

The FDA timeline for olanzapine LAI approval has not been disclosed. The NDA has been submitted, but regulatory review typically takes 10-12 months for standard applications.

How does this impact Medincell’s market position?

The Outperform rating and successful FDA approvals strengthen Medincell’s position in the psychiatric medication market, with BEPO technology providing a competitive advantage in long-acting injectable treatments.